Page last updated: 2024-09-05

sorafenib and Lung Neoplasms

sorafenib has been researched along with Lung Neoplasms in 254 studies

Research

Studies (254)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's52 (20.47)29.6817
2010's173 (68.11)24.3611
2020's29 (11.42)2.80

Authors

AuthorsStudies
Song, M1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Chen, TL; Hou, MH; Jain, V; Kuppusamy, R; Lee, TC; Lin, YW; Patel, AS; Su, TL1
Bharate, JB; Briggs, DC; Carlomagno, F; Frett, B; Kharbanda, A; Knowles, P; Lakkaniga, NR; Leung, YK; Li, HY; McDonald, NQ; Moccia, M; Santoro, M; Tran, P; Wang, X; Yan, W; Zhang, L1
Arthur, P; Gebeyehu, A; Kalvala, AK; Mondal, A; Nottingham, E; Patel, N; Rishi, AK; Singh, M; Surapaneni, SK1
Li, H; Liu, X; Zhang, J; Zhong, T1
Liu, X; Yi, Y1
Guan, XY; Li, GB; Ma, X; Song, C; Wang, HL; Yang, LL; Yu, YM1
Akutsu, N; Hirano, T; Ishigami, K; Kawakami, Y; Nakase, H; Numata, Y; Sasaki, S; Wagatsuma, K1
Fu, J; Hu, J; Liu, C; Qin, Y; Wu, W; Yin, J; Zhou, J1
Akula, S; Amanchi, NR; Ashireddygari, VR; Burra, VLSP; Kancha, RK; Korikani, M; Mullaguri, SC; Mupparapu, V; Sahoo, PS; Silveri, R; Subramanian, J1
Chen, X; Ren, J; Shao, M; Yang, H; Yang, W; Zheng, J1
Acharya, B; Frett, B1
Kang, T; Liao, D; Liu, W; Wang, X; Yu, X; Zeng, C; Zhang, R; Zhang, Y; Zhong, L1
Cai, M; Chen, J; Chen, Y; Guo, Y; Huang, J; Huang, W; Lai, M; Liang, L; Lin, L; Liu, M; Xie, L; Zhang, X; Zhang, Y; Zhu, K1
Acheampong, F; Halaweish, F; Mahnashi, M; Ostlund, T1
Jeon, MJ; Jin, M; Kim, BH; Kim, EY; Kim, M; Kim, WB; Kim, WG; Lim, DJ; Shin, DY; Shong, YK1
Amin, NH; El-Saadi, MT; Mohamed, NR; Sharkawi, MMZ1
Nijhawan, HP; Raut, HC; Yadav, KS1
Alahmad, W; Bellur Atici, E; Cetinkaya, A; Kaya, SI; Ozkan, SA1
Gupta, V; Shukla, SK1
Farrales, P; Gupta, V; Kanabar, DD; Kulkarni, NS; Kunda, NK; Muth, A; Parvathaneni, V; Shukla, SK1
Amos, C; Cheng, C; Schaafsma, E; Weng, YL; Zhao, Y1
Abdulla, DSY; Backes, H; Behringer, D; Buettner, R; Eichstaedt, M; Fischer, RN; Franklin, J; Frechen, S; Fuhr, U; Gardizi, M; Junge, L; Kaminsky, B; Kinzig, M; Kobe, C; Limburg, M; Mattonet, C; Merkelbach-Bruse, S; Michels, S; Nogova, L; Ouyang, D; Persigehl, T; Rokitta, D; Scheffler, M; Schnell, R; Sörgel, F; Sos, ML; Stelzer, C; Suleiman, AA; Taubert, M; Tian, Y; Wolf, J1
Fletcher, P; Kunene, V; Ma, YT; Razak, RA1
Han, BH; Huh, JD; Lee, SU; Seo, KI; Son, MY; Yun, BC1
Ling, X; Rao, Z; Wan, J; Wang, J; Zhou, M1
Fu, J; Wang, X; Yue, Q1
Harada, N; Iguchi, T; Iseda, N; Itoh, S; Kurihara, T; Mori, M; Morinaga, A; Nagao, Y; Shimagaki, T; Tomiyama, T; Toshima, T; Wang, H; Yoshizumi, T1
Cai, M; Huang, W; Xing, Y; Zhu, L; Zhuo, J1
Chao, Y; Chen, SC; Yang, MH1
DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q1
Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L1
Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R1
Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G1
Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W1
Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C1
Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Kosloff, RA; Quinn, R; Rubin, MS; Shih, KC; Shipley, DL; Spigel, DR1
Broggini, M; Caiola, E; Frapolli, R; Garassino, MC; Iezzi, A; Marabese, M; Tomanelli, M; Valerio, R1
Chayahara, N; Goto, H; Hirokawa, M; Imamura, Y; Ito, Y; Kasahara, T; Kiyota, N; Minami, H; Miya, A; Miyauchi, A; Mukohara, T; Nagatani, Y; Nibu, KI; Otsuki, N; Suto, H; Toyoda, M1
Duo, J; Ma, X; Zhao, Y; Zhu, H1
Cao, S; Chai, Y; Feng, F; Jiang, Q; Li, BA; Li, D; Li, X; Ren, T; Sun, H; Yang, R; Zhang, Y; Zhao, Q1
Han, G; Jang, HJ; Kim, S; Lee, SA; Seong, S1
Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T1
Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Kim, S; Koh, YI; Sim, DW; Yu, J1
Chen, X; Ma, S; Mei, Q; Wang, J; Wang, Z; Zhang, S1
Dai, JG; Huang, HH; Liang, Y1
Kim, DY; Kim, YJ; Lee, SJ; Lim, HY; Lim, TS; Park, JW; Ryoo, BY; Yoo, C; Yu, SJ1
Hu, D; Hu, Y; Li, J; Wang, X1
Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K; Watanabe, H1
Hino, H; Hiramoto, M; Kazama, H; Lorenzo, A; Miyazawa, K; Moriya, S; Okuma, T; Ota, K; Takano, N; Yokota, A1
Yang, X; Yi, C; Zhao, Y; Zhu, H1
Celine, J; Couvreur, K; Frederic, D; Marlies, B; Philippe, D; Randal, D; Sylvie, R1
Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD1
Jiang, W; Zeng, ZC1
Ewig, JM; Iyer, P; Mayer, JL1
Haraldsdottir, S; Ing, SW; Kendra, K; Li, Q; Olencki, TE; Villalona-Calero, MA1
Anthony Greco, F; Hainsworth, JD; Penley, WC; Shipley, DL; Thompson, DS; Waterhouse, DM; Webb, CD1
Gong, R; Liu, LR; Nie, LH; Song, TR; Wang, JZ; Wazir, R; Wei, Q; Zhao, RN1
Shen, HJ; Wang, YH; Xu, J1
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T1
Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY1
Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R1
Greer, PA; Leduc, C; Nagaria, TS; Sangrar, W; Squire, JA; Williams, JL1
He, X; Zhang, T1
Aronson, P; Uhlenhake, EE; Watson, AC1
Dermeche, S; Gravis, G; Guerin, M; Salem, N; Walz, J1
Hatano, E; Ishii, T; Seo, S; Taura, K; Uemoto, S; Yasuchika, K1
Bellesoeur, A; Billemont, B; Blanchet, B; Carton, E; Clerc, J; Goldwasser, F; Groussin, L; Mir, O1
Dowlati, A; Fu, P; Halmos, B; Ma, P; Mekhail, T; Nickolich, M; Pennell, N; Sharma, N1
Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M1
Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q1
Chang, H; Kim, KM; Kim, YJ; Lee, DW; Lee, HJ; Lee, JS1
Li, Z; Wang, K; Zhang, H1
Amann, J; Araujo, L; Carbone, DP; Greulich, H; Horn, L; Imielinski, M; Kaplan, B; Meyerson, M; Schiller, J; Villalona-Calero, MA1
Pitoia, F1
Chang, FY; Chao, TT; Chen, KF; Chen, PT; Chen, YL; Shiau, CW; Su, WP; Tai, WT; Wang, CY; Weng, CY; Yu, CJ; Yuan, A1
Dudek, A; Konety, SH; Masri, SC; Misselt, AJ1
Chen, XQ; Li, ZY; Lin, TY; Wang, YL1
Bella, A; Guerra, JR; Lolo, D; Suelves, AM1
Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E1
Bernards, R; Groenendijk, FH; Hauptmann, M; Horlings, HM; Jonkers, J; Mellema, WW; Schut, E; Smit, EF; van den Heuvel, MM; van der Burg, E; Willems, SM1
Guo, DH; Pei, F; Si, HY; Tang, ZH; Wang, DX; Wang, WL; Xiao, BK; Xie, TT; Zhang, XY; Zhu, M1
Akarsu, S; Çarsanbali, S; Fetil, E; İlknur, T; Lebe, B1
Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J1
Alexandre de Azevedo, R; Barbuto, JA; Bydlowski, SP; Ferreira, AK; Jorge, SD; Levy, D; Pizzo, CR; Rodrigues, CP; Salomon, MA; Teixeira, SF1
Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L1
Corssmit, EP; Kapiteijn, E; Links, TP; Oosting, SF; Schneider, TC; van der Horst-Schrivers, AN1
Fujii, Y; Hatano, T; Horie, S; Kawata, N; Kimura, G; Kondo, T; Kume, H; Morita, M; Murakami, M; Nakajima, K; Nakazawa, H; Ohno, Y; Okegawa, T; Oya, M; Saito, K; Takahashi, S; Wakumoto, Y; Yamaguchi, R1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ1
Bornemann, L; Dicken, V; Moltz, JH; Peitgen, HO; Scheuring, U; Zaim, S1
Gavrancic, T; Park, YH1
Ang, MK; Chau, NM; Chowbay, B; Haaland, B; Hui, KM; Koh, TS; Li, WY; Lim, WT; Ng, QS; Tan, DS; Tan, EH; Tan, IB; Thng, CH; Toh, CK1
Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U1
Huang, A; Shi, Y1
Albiges, L; Escudier, B1
Casado Sáenz, E; Falagan, S; García Sánchez, S; Gómez-Raposo, C; Hernández Jusdado, R; Moreno Rubio, J; Moreno, V; Sereno, M; Zambrana Tébar, F1
Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S1
Kim, JK; Seo, MS; Shim, JY1
Fujisawa, M; Harada, K; Imai, S; Miyake, H1
Ajiki, T; Fukumoto, T; Fukushima, K; Gon, H; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Shinzeki, M; So, S; Takebe, A; Tanaka, M; Urade, T1
Afaq, F; Athar, M; Diamond, AC; Elmets, CA; Kappes, JC; Katiyar, SK; Pal, HC; Strickland, LR1
Abou-Alfa, GK; Ang, C; Gamblin, TC; Gatalica, Z; He, R; Millis, SZ; Miura, JT; Reddy, SK; Xiu, J; Yee, NS1
Arén, O; de Marinis, F; Hirsh, V; Juhász, E; Mok, TS; Novello, S; Ong, TJ; Paz-Ares, L; Peña, C; Schmelter, T; Seto, T; Smit, EF; Sun, Y; Wakelee, HA; Wu, YL; Yang, JC; Zhang, L1
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M1
Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X1
Chen, C; Hu, H; Li, H1
Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS1
Horai, T; Horiike, A; Ishikawa, Y; Kaburaki, K; Kawano, Y; Kudo, K; Motoi, N; Nishio, M; Ohyanagi, F; Takeuchi, K; Tambo, Y; Tanimoto, A; Uenami, T; Yanagitani, N1
Bin, L; Heqing, Y; Linfa, L; Xuemei, Y1
Boone, DL; Booth, L; Chuckalovcak, J; Dent, P; Koromilas, AE; McGuire, WP; Poklepovic, A; Roberts, JL; Stringer, DK; Tavallai, M1
Jimenez, CR; Knol, JC; Lind, JS; Pham, TV; Rovithi, M; Smit, EF; Verheul, HM; Voortman, J1
Hu, P; Tang, F; Wang, Z; Xie, C1
He, J; Sun, J; Sun, T; Zeng, M; Zeng, Z; Zhang, S1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R1
Chikui, K; Igawa, T; Matsuo, M; Nakiri, M; Nishihara, K; Ogasawara, N; Suekane, S; Suyama, S; Ueda, K1
Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P1
Hong, TH; Kim, DG; Na, GH; You, YK1
Chen, KF; Fan, LC; Hung, MH; Jiang, JK; Shiau, CW; Tai, WT; Teng, HW; Yang, SH1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I1
Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH1
Fountas, A; Giotaki, Z; Kalogeropoulos, CD; Tigas, S; Tsatsoulis, A1
Booth, L; Dent, P; Poklepovic, A; Roberts, JL1
Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J1
Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Murakami, M; Noura, S; Shimizu, J; Shuto, T; Yasuyama, A; Yoshikawa, M1
Gettinger, S1
Blumenschein, G1
Adjei, AA1
Rey, PM; Villavicencio, H1
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I1
Döme, B; Magyar, M1
Chen, Q; Huang, WX; Li, XF; Ye, YB1
Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T1
Basso, U; Bertuzzi, A; Brunello, A; Santoro, A1
Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K1
Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T1
Clayman, GL; Herzog, CE; Sherman, SI; Waguespack, SG; Williams, MD1
Horn, L; Sandler, AB1
Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ1
Frieling, T; Heise, J; Wassilew, SW1
Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J1
Fukuoka, M; Hatashita, E; Nakagawa, K; Okamoto, I; Takezawa, K; Yamada, Y; Yonesaka, K1
Ye, SL1
Blumenschein, GR; Cihon, F; Cupit, L; Fossella, F; Gatzemeier, U; O'Leary, J; Reck, M; Stewart, DJ1
Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM1
Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S1
Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S1
Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J1
Furukawa, M; Hakariya, T; Ide, S; Ishimoto, H; Kohno, S; Nagashima, S; Nakamura, Y; Sawai, T; Soda, H; Takemoto, S; Tomari, S1
Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L1
Finn, RS; Saab, S; Yeganeh, M1
Liu, ZZ; Piao, Y; Xie, XD1
Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, ZJ1
Le Moulec, S; Loriot, Y; Soria, JC1
Chao, G; Dicker, DT; El-Deiry, WS; Ferrara, T; Katz, SI; Smith, CD; Wang, W; Zhou, L1
Hasskarl, J1
Altorki, NK; Alvarez, H; Beer, DG; Boonstra, JJ; Chaves, P; Darnton, SJ; Dinjens, WN; Eshleman, JR; Klimstra, DS; Lin, L; Pereira, AD; Ribeiro, C; Roque, L; Schrump, DS; Shimada, Y; Tang, LH; Tilanus, HW; van Dekken, H; van Marion, R1
Abe, K; Amagai, Y; Hojo, K; Ide, N; Iguchi, M; Kato, A; Matsumoto, M; Shichijo, M; Tanaka, H; Wada, T1
Kurashige, Y; Otani, A; Yoshimura, N1
Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Klar, U; Merk, J; Rolff, J; Sommer, A1
Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J1
Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ1
Dingemans, AM; Hochstenbach, MM; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ1
Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, W; Zhu, XD; Zhuang, PY1
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM1
Beck, J; Bellmunt, J; Escudier, B1
Antón-Torres, A; Bellmunt, J; Carles, J; Guillem, V; López-Martín, JA; Maroto-Rey, P; Trigo, JM; Urruticoechea, L1
de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C1
Chang, JW; Chang, NJ; Chuang, CK; Hou, MM; Hsieh, JJ; Hsu, T; Huang, HY; Wang, HM1
An, J; Bilenky, M; Birol, I; Butterfield, YS; Cezard, T; Chuah, E; Corbett, R; Fejes, AP; Griffith, M; Griffith, OL; Hirst, M; Holt, RA; Huntsman, DG; Jones, SJ; Laskin, J; Li, YY; Marra, MA; Martin, M; Mayo, M; Melnyk, N; Moore, RA; Morin, RD; Pugh, TJ; Severson, T; Shah, SP; Sutcliffe, M; Tam, A; Terry, J; Thiessen, N; Thomson, T; Varhol, R; Yee, J; Zeng, T; Zhao, Y1
Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D1
Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W1
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ1
Bury, MJ; Floyd, JD; Gandara, DR; Gitlitz, BJ; Glisson, BS; Ho, C; Moon, J; Reimers, HJ; Schulz, TK; Sundaram, PK1
Homma, Y; Kaneko, T; Matsushima, H; Morimoto, H; Tsuzaka, Y1
Halff, G; Speeg, KV; Wang, Y; Washburn, WK1
Jungmeechoke, K; Kanjanapayak, B; Ruangkanchanasetr, P1
Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R1
Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G1
Adjei, AA; Dy, GK; Hillman, SL; Mandrekar, S; Molina, JR; Nair, S; Rowland, KM; Schild, SE; Steen, PD; Wender, DB1
Cao, L; Choyke, P; Force, J; Giaccone, G; Gutierrez, M; Keen, C; Kelly, RJ; Kummar, S; Lopez-Chavez, A; Raffeld, M; Rajan, A; Steinberg, SM; Turkbey, B; Wright, JJ; Xi, L; Yu, Y1
Friedrich, MJ1
Liu, Y; Shi, Y; Sun, Y; Wang, L; Wang, Y; Yu, S; Zhang, X1
Clerc, J; Coriat, R; Goldwasser, F; Mir, O; Ropert, S1
Boeykens, E; Rutsaert, R; Stappaerts, I; Van Loo, S1
Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S1
El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L1
Block, MS; Kohli, M1
Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J1
An, S; Choe, TB; Hong, SI; Jin, HO; Kim, YS; Lee, KH; Lee, SJ; Park, IC; Seo, SK; Woo, SH1
Dombi, E; Force, J; Giaccone, G; Rajan, A; Steinberg, SM1
Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F1
Dai, Z; Fan, J; Hu, J; Huang, XW; Qiu, SJ; Tan, CJ; Wang, Z; Zhou, J1
Curtit, E; Le Tourneau, C; Mansi, L; Medioni, J; Viel, E1
Adjei, AA; Blumenschein, GR; Gatzemeier, U; Heigener, D; Hillman, S; Mandrekar, S1
Keresztes, RS; Wu, S1
Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C1
Aguillo Gutiérrez, E; Altemir Trallero, J; Cabrejas Gómez, Mdel C; Lázaro Sierra, J; Ocón Bretón, J1
Adamus, G; Anitori, R; Golchet, P; Jampol, LM; Mets, RB; Shaw, J; Wilson, D1
Henmi, S; Inuzuka, T; Kimura, T; Kita, R; Kudo, M; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Sekikawa, A; Takeda, H1
Chang, C; Hsu, CL; Huang, CK; Hung, YC; Jeng, LB; Lin, TY; Ma, WL; Wu, MH; Yeh, CC; Yeh, S1
Camidge, DR; Dasari, A; Diab, S; Drabkin, HA; Flaig, TW; Gore, L; Jimeno, A; Lewis, KD; Messersmith, WA; Weekes, CD1
Jung, CK; Kang, JH; Kim, JO; Oh, JE; Shin, JY; Yoon, SA; Zhang, XH1
Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS1
Chan, SL; Johnson, P1
Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, Y; Wang, ZJ1
Lucas, LM1
Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D1
Gold, KA; Kim, E; Zhang, J1
Chen, J; Chen, L; Jiang, Y; Li, C; Li, Y; Ma, Y1
Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R1
Bria, E; Pilotto, S; Tortora, G1
Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L1
Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E1
Arao, T; Arii, S; Hagiwara, S; Haji, S; Hakamada, K; Hiasa, Y; Hidaka, H; Hirooka, M; Hisai, H; Iso, Y; Izumi, N; Kanazawa, A; Kimura, H; Kubota, K; Kudo, M; Kumada, T; Kuzuya, T; Matsumoto, K; Nagai, T; Nishio, K; Sakurai, T; Sato, S; Shimada, M; Toyoda, H; Toyoki, Y; Tsuchiya, K; Ueshima, K; Utsunomiya, T; Yasui, K1
Brümmendorf, TH; Gambacorti-Passerini, C; Wege, H1
Boni, C; Bracarda, S; Caserta, C; Cinquini, M; Cortesi, E; De Angelis, V; Di Costanzo, F; Falcone, A; Gasparro, D; Labianca, R; Mucciarini, C; Paglino, C; Pazzola, A; Porta, C; Santoro, A1
Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM1
Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S1
Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I1
Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF1
Hegde, U; Kaloudis, E; Patel, V1
Burgers, SA; Dingemans, AM; Groen, HJ; Heideman, DA; Kunst, PW; Mellema, WW; Smit, EF; Thunnissen, E; van Wijk, A1
Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A1
Brandt, R; Dredge, K; Hammond, E1
Götz, R; Kramer, BW; Rapp, UR1
Herbst, RS; Onn, A; Sandler, A1
Schiller, JH; Wakelee, HA1
Baek, WS; Pytel, P; Rubeiz, H; Undevia, SD1
Ardizzoni, A; Franciosi, V; Tiseo, M1
Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X1
Chung, NM; Gutierrez, M; Turner, ML1
Fesik, SW; Huang, X; Li, L; Lin, X; Morgan-Lappe, S; Shen, Y; Vernetti, LA; Zakula, DM1
Azad, NS; Cowen, EW; Dahut, W; Gutierrez, M; Kong, HH; Turner, ML1
Herbst, RS1
Grossman, ME; MacGregor, JL; Sherman, WH; Silvers, DN1
Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A1
Alexandrescu, DT; Dasanu, CA; Dutcher, J1
Dudek, AZ; Mulamalla, K; Truskinovsky, AM1
Hanna, N1
Ardizzoni, A; Tiseo, M1
De Mulder, PH; Mulder, SF; van Spronsen, DJ1
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C1
Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P1
Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A1
Cabebe, E; Wakelee, H1
Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM1
Alba, E; Medina, MA; Quesada, AR1
Stewart, DJ1
Fenning, R; Gudena, V; Kizziah, M; Montero, AJ; Post, G; Verma, N1
Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E1
Buhl, R; Fischer, B1

Reviews

27 review(s) available for sorafenib and Lung Neoplasms

ArticleYear
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    International immunopharmacology, 2022, Volume: 112

    Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Mutation; Prospective Studies; Sorafenib

2022
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Expert opinion on therapeutic patents, 2022, Volume: 32, Issue:10

    Topics: Humans; Lung Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Sorafenib; Transfection

2022
Angiogenesis Inhibitors in NSCLC.
    International journal of molecular sciences, 2017, Sep-21, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids

2017
Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.
    Medicine, 2018, Volume: 97, Issue:42

    Topics: Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Heart Atria; Heart Neoplasms; Humans; Killer Cells, Natural; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Remission Induction; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tumor Burden

2018
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
    International urology and nephrology, 2013, Volume: 45, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Fatal Outcome; Humans; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Rare Diseases; Risk Assessment; Sorafenib; Tomography, X-Ray Computed

2013
Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:14

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2014
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A

2015
The role and mechanism of autophagy in sorafenib targeted cancer therapy.
    Critical reviews in oncology/hematology, 2016, Volume: 100

    Topics: Animals; Autophagy; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2016
Targeted therapy in advanced non-small-cell lung cancer.
    Seminars in respiratory and critical care medicine, 2008, Volume: 29, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2008
Sorafenib in lung cancer: clinical developments and future directions.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Forecasting; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factors

2008
K-ras as a target for lung cancer therapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2

    Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sensitivity and Specificity; Sorafenib; Survival Analysis; Treatment Outcome

2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
    Magyar onkologia, 2008, Volume: 52, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones

2008
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Clinical lung cancer, 2009, Volume: 10 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2009
Targeted therapies in the treatment of advanced/metastatic NSCLC.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:14

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2009
Sorafenib.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2010
Classic biphasic pulmonary blastoma: a case report and review of the literature.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Fatal Outcome; Humans; Intestinal Perforation; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pulmonary Blastoma; Pyridines; Sorafenib

2011
[Targeting the RAS signalling pathway in cancer].
    Bulletin du cancer, 2011, Volume: 98, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib

2011
Sorafenib in non-small cell lung cancer.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:9

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
    Magyar onkologia, 2012, Volume: 56, Issue:3

    Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2012
Angiogenesis and lung cancer: prognostic and therapeutic implications.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-10, Volume: 23, Issue:14

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib

2005
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
    Clinical lung cancer, 2005, Volume: 7 Suppl 1

    Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2005
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 2

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2006
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Clinical lung cancer, 2006, Volume: 8 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors

2006
Combination of target agents: challenges and opportunities.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:5 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Current treatment options in oncology, 2007, Volume: 8, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1

2007
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    BioEssays : news and reviews in molecular, cellular and developmental biology, 2007, Volume: 29, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
[Lung cancer].
    Medizinische Klinik (Munich, Germany : 1983), 2008, May-15, Volume: 103, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib

2008

Trials

43 trial(s) available for sorafenib and Lung Neoplasms

ArticleYear
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
    Cancer medicine, 2020, Volume: 9, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins p21(ras); Sorafenib

2020
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Lung cancer (Amsterdam, Netherlands), 2017, Volume: 113

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Fatigue; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
    Cancer investigation, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Treatment Outcome

2013
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Sorafenib; Treatment Outcome

2014
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinogenesis; China; ErbB Receptors; Female; Genotype; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sequence Deletion; Sorafenib; Survival Analysis; Treatment Failure

2014
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
    International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Female; Humans; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2015
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult

2015
Comparison of volumetric and linear serial CT assessments of lung metastases in renal cell carcinoma patients in a clinical phase IIB study.
    Academic radiology, 2015, Volume: 22, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Tomography, X-Ray Computed; Tumor Burden

2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib

2015
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Canc
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sorafenib; Treatment Outcome

2015
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 93

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Risk Factors; Sorafenib; Treatment Outcome

2016
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.
    Proteomics. Clinical applications, 2016, Volume: 10, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins p21(ras); Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome

2016
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
    Cancer, 2009, Jan-15, Volume: 115, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2009
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2009
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Investigational new drugs, 2010, Volume: 28, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Demography; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Radiography; Sorafenib; Treatment Outcome

2010
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate

2010
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-10, Volume: 28, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2010
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jun-01, Volume: 16, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors

2010
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib

2010
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    European radiology, 2010, Volume: 20, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2011
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Sorafenib; Survival Rate; Treatment Outcome

2010
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Failure; Treatment Outcome

2011
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome

2011
A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
    Cancer, 2010, Dec-15, Volume: 116, Issue:24

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib

2010
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Genes, ras; Humans; Lung Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib

2011
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Sorafenib

2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome

2011
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:7

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Retrospective Studies; Sorafenib; Sulfonamides; Survival Rate; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2011
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.
    Clinical lung cancer, 2011, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome

2011
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat

2013
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-01, Volume: 30, Issue:25

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome

2012
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
    European urology, 2013, Volume: 63, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Recombinant Proteins; Sorafenib; Treatment Outcome

2013
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Survival Rate

2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes

2012
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
    British journal of cancer, 2012, Nov-20, Volume: 107, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2012
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-01, Volume: 19, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Platinum; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Treatment Outcome

2013
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Clinical lung cancer, 2013, Volume: 14, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed

2013
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome

2006
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-01, Volume: 13, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib

2007
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
    Clinical lung cancer, 2007, Volume: 8, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate

2007

Other Studies

184 other study(ies) available for sorafenib and Lung Neoplasms

ArticleYear
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
    Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Kinesins; Lung Neoplasms; Models, Molecular; Protein Conformation

2015
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[
    Journal of medicinal chemistry, 2021, 09-09, Volume: 64, Issue:17

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Squamous Cell; Neovascularization, Pathologic; Phthalazines; Small Cell Lung Carcinoma; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2021
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Adenocarcinoma of Lung; Apoptosis; Cell Proliferation; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured; Wound Healing

2022
Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.
    Anticancer research, 2021, Volume: 41, Issue:9

    Topics: Acrylamides; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Pyrimidines; Sorafenib; Spheroids, Cellular; Spiro Compounds; Telmisartan; Thiadiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021
Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of
    Drug delivery, 2021, Volume: 28, Issue:1

    Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Chemistry, Pharmaceutical; Crizotinib; Drug Carriers; Drug Combinations; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice, Nude; Nanoparticles; Polymers; Sorafenib; Xenograft Model Antitumor Assays

2021
Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.
    Immunotherapy, 2021, Volume: 13, Issue:17

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Budd-Chiari Syndrome; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Sorafenib

2021
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
    Pharmacological research, 2022, Volume: 177

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirtuin 2; Sorafenib; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays

2022
A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases.
    Clinical journal of gastroenterology, 2022, Volume: 15, Issue:5

    Topics: Carcinoma, Hepatocellular; Drugs, Investigational; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Skull; Sorafenib; Tegafur

2022
N-acetyl-galactosamine modified metal-organic frameworks to inhibit the growth and pulmonary metastasis of liver cancer stem cells through targeted chemotherapy and starvation therapy.
    Acta biomaterialia, 2022, 10-01, Volume: 151

    Topics: Animals; Asialoglycoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Galactosamine; Glucose; Glucose Oxidase; Liver Neoplasms; Lung Neoplasms; Metal-Organic Frameworks; Mice; Neoplastic Stem Cells; Sorafenib

2022
Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.
    Toxicology and applied pharmacology, 2022, 10-15, Volume: 453

    Topics: Cell Line, Tumor; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib

2022
Targeting the Lysosomal Degradation of Rab22a-NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023, Volume: 10, Issue:5

    Topics: Humans; Lung Neoplasms; Lysosomes; Oncogene Proteins, Fusion; Osteosarcoma; Protein Kinases; rab GTP-Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases

2023
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases.
    Cell death & disease, 2023, 01-13, Volume: 14, Issue:1

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Signal Transduction; Sorafenib; Tumor Microenvironment

2023
Estrone analogs as potential inhibitors targeting EGFR-MAPK pathway in non-small-cell lung cancer.
    Chemical biology & drug design, 2023, Volume: 101, Issue:6

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin D; ErbB Receptors; Estrone; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Sorafenib

2023
Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
    Endocrine, 2023, Volume: 81, Issue:2

    Topics: Biomarkers; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphocytes; Neutrophils; Prognosis; Retrospective Studies; Sorafenib; Thyroid Neoplasms

2023
Determination of Gemcitabine and Sorafenib in Spiked Human Plasma Using Multivariate Model Update Chemometric Methods.
    Journal of AOAC International, 2023, Nov-02, Volume: 106, Issue:6

    Topics: Carcinoma, Non-Small-Cell Lung; Chemometrics; Gemcitabine; Humans; Lung Neoplasms; Pharmaceutical Preparations; Sorafenib; United States

2023
Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells.
    Pharmaceutical development and technology, 2023, Volume: 28, Issue:8

    Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Polyesters; Polymers; Sorafenib

2023
Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib.
    Analytica chimica acta, 2023, Nov-01, Volume: 1280

    Topics: Carcinoma, Non-Small-Cell Lung; Electrochemical Techniques; Electrodes; Humans; Limit of Detection; Lung Neoplasms; Molecular Imprinting; Molecularly Imprinted Polymers; Polymers; Sorafenib; Zinc Oxide

2023
Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective.
    Therapeutic delivery, 2020, Volume: 11, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Lung Neoplasms; Nanotechnology; Sorafenib

2020
Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
    Pharmaceutical research, 2020, Mar-12, Volume: 37, Issue:3

    Topics: Administration, Inhalation; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cations; Cell Line, Tumor; Drug Carriers; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Polymers; Sorafenib

2020
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    International journal of cancer, 2020, 11-01, Volume: 147, Issue:9

    Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Datasets as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Liver Neoplasms; Logistic Models; Lung Neoplasms; Models, Genetic; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; RNA-Seq; Signal Transduction; Sorafenib; Transcriptome

2020
Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma.
    Journal of clinical gastroenterology, 2021, 02-01, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gastric Acid; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; United Kingdom

2021
[Gallbladder Perforation after Transarterial Chemoembolization in a Patient with a Huge Hepatocellular Carcinoma].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2020, 06-25, Volume: 75, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cholecystitis; Gallbladder; Humans; Liver; Liver Neoplasms; Lung Neoplasms; Male; Sorafenib; Tomography, X-Ray Computed

2020
A cell membrane vehicle co-delivering sorafenib and doxorubicin remodel the tumor microenvironment and enhance immunotherapy by inducing immunogenic cell death in lung cancer cells.
    Journal of materials chemistry. B, 2020, 09-14, Volume: 8, Issue:34

    Topics: Biological Transport; Cell Death; Cell Line, Tumor; Cell Membrane; Combined Modality Therapy; Doxorubicin; Drug Carriers; Humans; Immunotherapy; Lung Neoplasms; Sorafenib; Tumor Microenvironment

2020
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer.
    Biochemical and biophysical research communications, 2020, 09-03, Volume: 529, Issue:4

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Sorafenib; Up-Regulation

2020
[Immune Response on Outcomes in Hepatocellular Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:9

    Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Sorafenib; Tumor Microenvironment

2020
Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2.
    Experimental cell research, 2021, 09-01, Volume: 406, Issue:1

    Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Movement; Cell Proliferation; Drug Carriers; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gold; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; MCF-7 Cells; Melanoma, Experimental; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Zonula Occludens-1 Protein

2021
Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
    The American journal of gastroenterology, 2017, Volume: 112, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
    Oncotarget, 2017, May-09, Volume: 8, Issue:19

    Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Disease Models, Animal; DNA; Doxorubicin; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Osteosarcoma; Phenylurea Compounds; RNA; Sorafenib; Xenograft Model Antitumor Assays

2017
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
    The Journal of pharmacology and experimental therapeutics, 2017, Volume: 362, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays

2017
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
    Stem cell research & therapy, 2017, 05-25, Volume: 8, Issue:1

    Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred NOD; Mice, SCID; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Sorafenib; Time Factors

2017
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Biomaterials, 2017, Volume: 143

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chitosan; Delayed-Action Preparations; Disaccharides; Drug Synergism; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Lung Neoplasms; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Porosity; Rats; Silicon Dioxide; Sorafenib; Triterpenes; Ursolic Acid

2017
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    British journal of cancer, 2017, Sep-26, Volume: 117, Issue:7

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays

2017
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
    Scientific reports, 2018, 01-17, Volume: 8, Issue:1

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Humans; Lung Neoplasms; Mutation; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Pyrimidinones; Sorafenib

2018
Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Auris, nasus, larynx, 2018, Volume: 45, Issue:6

    Topics: Aged; Antineoplastic Agents; Drug Substitution; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Radiation Tolerance; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2018
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
    Medicine, 2018, Volume: 97, Issue:25

    Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed

2018
Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.
    Cell death & disease, 2018, 07-03, Volume: 9, Issue:7

    Topics: ADAM17 Protein; Animals; Blotting, Western; Carcinoma, Hepatocellular; Enzyme Inhibitors; Flow Cytometry; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Sorafenib

2018
Combined Treatment for Lung Metastasis from Hepatocellular Carcinoma: A Case Report.
    Explore (New York, N.Y.), 2018, Volume: 14, Issue:5

    Topics: Acupuncture; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Medicine, Korean Traditional; Middle Aged; Phytotherapy; Quality of Life; Sorafenib

2018
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
    International heart journal, 2018, Sep-26, Volume: 59, Issue:5

    Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A

2018
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
    Investigational new drugs, 2019, Volume: 37, Issue:5

    Topics: Animals; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Therapy, Combination; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019
Clinical Drug Response Prediction by Using a Lq Penalized Network-Constrained Logistic Regression Method.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 51, Issue:5

    Topics: Algorithms; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; Erlotinib Hydrochloride; Female; Gene Expression Regulation; Gene Regulatory Networks; Genome, Human; Humans; Logistic Models; Lung Neoplasms; Male; Models, Biological; Precision Medicine; Sorafenib; Transcriptome

2018
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Investigational new drugs, 2019, Volume: 37, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome

2019
Symptomatic treatment of brain metastases in renal cell carcinoma with sorafenib.
    Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement

    Topics: Aged; Asian People; Brain Neoplasms; Carcinoma, Renal Cell; Fatal Outcome; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Lung Neoplasms; Protein Kinase Inhibitors; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2018
Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
    Anticancer research, 2019, Volume: 39, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome

2019
Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
    Oncology reports, 2019, Volume: 42, Issue:1

    Topics: A549 Cells; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Sorafenib

2019
Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report.
    Medicine, 2019, Volume: 98, Issue:20

    Topics: alpha-Fetoproteins; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Sorafenib; Treatment Outcome

2019
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
    Acta clinica Belgica, 2020, Volume: 75, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Adenoid Cystic; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Pericardium; Pleural Neoplasms; Progression-Free Survival; Retrospective Studies; Salivary Gland Neoplasms; Sorafenib

2020
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Immunocompromised Host; Immunosuppressive Agents; K562 Cells; Killer Cells, Natural; Lectins, C-Type; Liver Neoplasms; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2013
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
    Oncology, 2013, Volume: 84 Suppl 1

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Ethiodized Oil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Retrospective Studies; Sorafenib; Survival Rate

2013
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
    Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:1

    Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2014
Case of sorafenib-induced thyroid storm.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

    Topics: Adrenal Gland Neoplasms; Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Heart Arrest; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Respiratory Aspiration; Sorafenib; Thyroid Crisis; Thyroid Hormones

2013
[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Burden

2013
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19

    Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2013
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
    Angiogenesis, 2013, Volume: 16, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid

2013
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
    Onkologie, 2013, Volume: 36, Issue:6

    Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome

2013
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
    Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; Drug Synergism; ErbB Receptors; Female; Flavonoids; Humans; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; raf Kinases; ras Proteins; Receptor, ErbB-2; Sorafenib; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2013
Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
    Cell biochemistry and biophysics, 2014, Volume: 68, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Interphase; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Taxoids

2014
Sorafenib induced eruptive melanocytic lesions.
    Dermatology online journal, 2013, May-15, Volume: 19, Issue:5

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Humans; Kidney Neoplasms; Lentigo; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
    World journal of surgical oncology, 2013, Sep-27, Volume: 11

    Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2013
High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter.
    Surgery today, 2014, Volume: 44, Issue:10

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Rate

2014
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:3

    Topics: Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroglobulin; Thyroid Neoplasms

2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    European journal of endocrinology, 2014, Volume: 170, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome

2014
Sorafenib-induced tumor response in a patient with metastatic epithelioid angiomyolipoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-10, Volume: 32, Issue:11

    Topics: Adult; Angiomyolipoma; Antineoplastic Agents; Biopsy, Needle; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2014
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
    Oncology reports, 2014, Volume: 31, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2014
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA, Neoplasm; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Sorafenib

2014
Response to sorafenib treatment in advanced metastatic thyroid cancer.
    Arquivos brasileiros de endocrinologia e metabologia, 2014, Volume: 58, Issue:1

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome

2014
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4

    Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Survival; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Radiation recall reaction causing cardiotoxicity.
    Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2014, Apr-22, Volume: 16

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Chemoradiotherapy; Coronary Angiography; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Myocarditis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiation Dosage; Radiation Injuries; Risk Factors; Sorafenib; Whole Body Imaging

2014
Therapeutic effects of sorafenib on the A549/DDP human lung adenocarcinoma cell line in vitro.
    Molecular medicine reports, 2014, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors

2014
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
    BMJ case reports, 2014, May-19, Volume: 2014

    Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, Hepatocellular; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Scrotum; Severity of Illness Index; Sorafenib; Syndrome; Treatment Outcome

2014
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
    Anti-cancer drugs, 2014, Volume: 25, Issue:10

    Topics: Adult; Antineoplastic Agents; Axilla; Combined Modality Therapy; Dioxoles; Epirubicin; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sarcoma, Synovial; Sorafenib; Tetrahydroisoquinolines; Trabectedin

2014
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:8

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib

2014
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
    BMC cancer, 2014, Oct-10, Volume: 14

    Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays

2014
Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:8

    Topics: Antineoplastic Agents; Benzoxazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib

2014
To treat or not to treat: developments in the field of advanced differentiated thyroid cancer.
    The Netherlands journal of medicine, 2014, Volume: 72, Issue:8

    Topics: Adenocarcinoma, Follicular; Aged; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2014
A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2015
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:3

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vinblastine; Vinorelbine

2015
Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:11

    Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Rats; Sorafenib

2015
Sorafenib-Sunitinib Sequence: The Jury Is Out.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2015
A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
    Anti-cancer drugs, 2015, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib

2015
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
    Clinical journal of gastroenterology, 2015, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis

2015
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma.
    Yonsei medical journal, 2015, Volume: 56, Issue:5

    Topics: Aged; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2016
[Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:9

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib

2015
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
    Oncotarget, 2016, Jan-12, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Movement; Cells, Cultured; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Flavonoids; Flavonols; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma; Mice, Nude; Mutation; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2016
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
    Journal of surgical oncology, 2016, Volume: 113, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Tumor Suppressor Protein p53

2016
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
    European urology, 2016, Volume: 70, Issue:3

    Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment

2016
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
    Cancer science, 2016, Volume: 107, Issue:4

    Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Metformin; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thioredoxins; Transcription Factors; Xenograft Model Antitumor Assays

2016
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib

2015
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 93

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2016
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
    Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells.
    Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Stability; Signal Transduction; Sorafenib

2016
Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Radiotherapy, Intensity-Modulated; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    European urology, 2016, Volume: 70, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden

2016
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
    Journal of medical case reports, 2016, Jun-16, Volume: 10

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Time; Treatment Outcome

2016
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
    BMC cancer, 2016, 07-07, Volume: 16

    Topics: Aged; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Treatment Outcome

2016
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
    World journal of gastroenterology, 2016, Jul-07, Volume: 22, Issue:25

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sirolimus; Sorafenib

2016
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Oncotarget, 2016, Sep-27, Volume: 7, Issue:39

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Movement; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial-Mesenchymal Transition; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; RNA Interference; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays

2016
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.
    Oncology, 2016, Volume: 91, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Fever; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2016
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Yonsei medical journal, 2017, Volume: 58, Issue:1

    Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib

2017
Choroidal metastasis from papillary thyroid cancer: An unusual feature of a common disease.
    Annales d'endocrinologie, 2017, Volume: 78, Issue:1

    Topics: Antineoplastic Agents; Bone Neoplasms; Choroid Neoplasms; Female; Goiter, Nodular; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy

2017
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
    Oncotarget, 2017, Feb-21, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sorafenib; Xenograft Model Antitumor Assays

2017
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
    European radiology, 2017, Volume: 27, Issue:9

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2017
[Treatment Experience with Sorafenib for Lung Metastases of Hepatocellular Carcinoma Complicated with Interstitial Pneumonia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2016
Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
    Oncology, 2008, Volume: 74, Issue:3-4

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Dialysis; Sorafenib

2008
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib

2009
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
    Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thymus Neoplasms; Tomography, X-Ray Computed

2009
Sorafenib is active on lung metastases from synovial sarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sarcoma, Synovial; Sorafenib; Time Factors; Treatment Outcome

2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2009
Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib

2009
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2009, Volume: 19, Issue:4

    Topics: Adolescent; Benzenesulfonates; Carcinoma, Papillary; Child; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2009
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:28-29

    Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhea; Fatal Outcome; Humans; Ileostomy; Intestinal Perforation; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib; Ulcer

2009
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Cancer research, 2009, Aug-15, Volume: 69, Issue:16

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin E; Drug Delivery Systems; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, ras; Genotype; Humans; Lung Neoplasms; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2009
[Expert consensus on standardization of the management of primary liver cancer].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:6

    Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Congresses as Topic; Hepatectomy; Hepatic Artery; Humans; Liver Transplantation; Lung Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Radiotherapy, Conformal; Sorafenib; Ultrasonography

2009
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms

2010
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2010
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 67, Issue:2

    Topics: Antineoplastic Agents; Asian People; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
    British journal of cancer, 2010, Jan-19, Volume: 102, Issue:2

    Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib

2010
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2009, Volume: 9, Issue:12

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
[Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib

2009
[Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Fatigue; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2009
[Targeting KRAS pathway in NSCLC therapy].
    Bulletin du cancer, 2009, Volume: 96 Suppl

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib

2009
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Cancer biology & therapy, 2009, Volume: 8, Issue:24

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lung Neoplasms; Mesothelioma; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand

2009
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
    Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, Large Cell; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; DNA Fingerprinting; Esophageal Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Niacinamide; Oligonucleotides; Oligopeptides; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Stomach Neoplasms; Tandem Repeat Sequences; Telomerase; United States

2010
Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate

2010
Choroidal metastasis of renal cell carcinoma: a case report.
    Japanese journal of ophthalmology, 2010, Volume: 54, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Choroid Neoplasms; Eye Enucleation; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epothilones; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays

2010
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib; Survival Rate; Treatment Outcome

2010
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-01, Volume: 16, Issue:13

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Liposomes; Liver Neoplasms, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays; Zoledronic Acid

2010
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib

2011
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
    Clinical drug investigation, 2010, Volume: 30, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free Survival; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Translocation, Genetic; Treatment Outcome; Young Adult

2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
    Genome biology, 2010, Volume: 11, Issue:8

    Topics: Adenocarcinoma; Benzenesulfonates; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Selection, Genetic; Sorafenib; Sunitinib; Tongue Neoplasms

2010
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2010
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:11

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brachytherapy; Carcinoma, Hepatocellular; Cause of Death; Combined Modality Therapy; Follow-Up Studies; Humans; Iodine Radioisotopes; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Patient Care Planning; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Time Factors

2010
[Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Tomography, X-Ray Computed; Uracil

2010
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
    World journal of gastroenterology, 2010, Nov-21, Volume: 16, Issue:43

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome

2010
Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Kidney Neoplasms; Kidney Transplantation; Lung Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib

2011
NSCLC drug targets acquire new visibility.
    Journal of the National Cancer Institute, 2011, Mar-02, Volume: 103, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome

2011
A painful cranial bulge.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Niacinamide; Occipital Bone; Pain; Parietal Bone; Phenylurea Compounds; Pyridines; Skull Neoplasms; Sorafenib; Temporal Bone; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2011
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2011
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
    International journal of oncology, 2011, Volume: 39, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2011
Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroxine

2011
Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
    Biochemical pharmacology, 2011, Aug-01, Volume: 82, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survivin; TOR Serine-Threonine Kinases

2011
Severe sorafenib-induced hand-foot skin reaction.
    Dermatology online journal, 2011, May-15, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Disease Progression; Drug Eruptions; Fatal Outcome; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Chemotherapy, Adjuvant; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays

2011
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
    Cancer investigation, 2011, Volume: 29, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Indoles; Intestinal Perforation; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Vascular Endothelial Growth Factor A; Wound Healing

2011
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
    British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays

2011
[Long-standing differentiated thyroid carcinoma].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillary; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Diagnostic Errors; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Niacinamide; Palliative Care; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Tuberculosis, Miliary

2012
Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:9

    Topics: Aged; Autoantibodies; Benzenesulfonates; Carcinoma, Bronchogenic; Cell Proliferation; Eye Proteins; Fatal Outcome; Fluorescein Angiography; Functional Laterality; Humans; Lung Neoplasms; Male; Melanocytes; Niacinamide; Ophthalmoscopy; Paraneoplastic Syndromes; Phenylurea Compounds; Plasmapheresis; Pyridines; Retina; Sorafenib; Tomography, Optical Coherence; Uveal Diseases; Visual Acuity; Visual Fields

2011
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
    Oncology, 2011, Volume: 81 Suppl 1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Treatment Outcome

2011
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:1

    Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Random Allocation; Receptors, Androgen; Sorafenib; Tumor Cells, Cultured

2012
Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Cancer letters, 2012, Sep-28, Volume: 322, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2012
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:5

    Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography

2012
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2012
Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Bronchial Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2012
Painful leg mass.
    The Journal of family practice, 2012, Volume: 61, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neoplasms; Leg; Liver Neoplasms; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Pain; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Tomography, X-Ray Computed

2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed

2012
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Clinical laboratory, 2012, Volume: 58, Issue:5-6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2012
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
    Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:8

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome

2012
Sorafenib for lung cancer: is the "Battle" still open?
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:10

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2012
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2012, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2012
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA, Neoplasm; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Incidence; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Heterologous; Treatment Outcome

2013
A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib

2013
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
    Current pharmaceutical design, 2013, Volume: 19, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry

2013
Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
    International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Lung; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib

2013
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Saponins; Sorafenib

2012
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
    BMC cancer, 2004, Jun-01, Volume: 4

    Topics: Adenoma; Animals; Apoptosis; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Division; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2004
Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
    Journal of neuro-oncology, 2005, Volume: 74, Issue:2

    Topics: Adult; Benzenesulfonates; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Nerve Sheath Neoplasms; Neurofibroma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spinal Cord Neoplasms

2005
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays

2007
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
    Archives of dermatology, 2006, Volume: 142, Issue:11

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Foot; Hand; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome; Vasculitis, Leukocytoclastic, Cutaneous

2006
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Oncogene, 2007, Jun-07, Volume: 26, Issue:27

    Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Blotting, Western; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; RNA Interference; RNA, Small Interfering; Roscovitine; Sorafenib; Sulfonamides; Transmembrane Activator and CAML Interactor Protein; Zinc Fingers

2007
Keratoacanthomas associated with sorafenib therapy.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:1

    Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanthoma; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neck; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib

2007
Sorafenib-induced erythema multiforme.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:3

    Topics: Administration, Oral; Benzenesulfonates; Erythema Multiforme; Female; Humans; Lung Neoplasms; Melanoma, Amelanotic; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2007
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    The oncologist, 2007, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
    Southern medical journal, 2007, Volume: 100, Issue:3

    Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Spinal Neoplasms

2007
Pulmonary blastoma with renal metastasis responds to sorafenib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4

    Topics: Administration, Oral; Adult; Benzenesulfonates; Biopsy, Needle; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Neoplasms; Lung Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonectomy; Pulmonary Blastoma; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome

2007
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
    Onkologie, 2007, Volume: 30, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2007
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
    Praxis, 2007, May-02, Volume: 96, Issue:18

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed

2007
ASCO 2007: plenary top 5.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Medical Oncology; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Societies, Medical; Sorafenib; United States

2007
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Journal of the National Cancer Institute, 2007, Oct-03, Volume: 99, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome

2007
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
    Journal of the National Cancer Institute, 2008, Mar-19, Volume: 100, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome

2008
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
    Cancer biology & therapy, 2008, Volume: 7, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Nerve Sheath Neoplasms; Neurilemmoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiography, Thoracic; Sorafenib; Thoracic Wall; Treatment Outcome

2008
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate

2007